



IAP6 Rec'd PCT/PTO 16 APR 2007

AMENDMENT TRANSMITTAL LETTER

Docket No.
0933-0249PUS1Application No.
10/539,565Filing Date
June 17, 2005Examiner
Not Yet AssignedArt Unit
N/A

Applicant(s): Tarja LAITINEN et al.

Invention: ASTHMA SUSCEPTIBILITY LOCUS

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED						
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate		
Total Claims	41	- 41 =	0	x	25.00	0.00
Independent Claims	5	- 5 =	0	x	100.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>						
Other fee (please specify):						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:						0.00

☐ Large Entity☒ Small Entity☒ No additional fee is required for this amendment.☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.☐ A check in the amount of \$ _____ is enclosed.☐ Payment by credit card. Form PTO-2038 is attached.☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-2448
as described below. A duplicate copy of this sheet is enclosed.☒ Credit any overpayment.☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.Gerald M. Murphy, Jr.
Attorney Reg. No.: 28,977

Dated: April 16, 2007

BIRCH, STEWART, KOLASCH & BIRCH, LLP
12770 High Bluff Drive
Suite 260
San Diego, California 92130
(858) 792-8855



BOX SEQUENCE
PATENT
0933-0249PUS1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Tarja LAITINEN et al.

Application No.: 10/539,565

Confirmation No.: 4520

Filed: June 17, 2005

Art Unit: N/A

For: ASTHMA SUSCEPTIBILITY LOCUS

Examiner: Not Yet Assigned

AMENDMENT

Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Defective Response mailed March 15, 2007, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

This Reply includes:

- Amendments** to the Specification begin on page 2 of this paper.
- Amendments** to the Sequence Listing begin on page 5 of this paper.
- Remarks/Arguments** begin on page 6 of this paper.
- An **Appendix** including the paper and CRF disk copy of the Sequence Listing is attached following page 6 of this paper.